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Abstract
Background: Matrix metalloproteases (MMPs) are proteolytic enzymes that contribute to all stages of tumour
progression, including the later stages of invasion and metastasis. Genetic variants in the MMP genes may
influence the biological function of these enzymes and change their role in carcinogenesis and progression. We
have investigated the association between the -735 C/T, the -1171 5A/6A, and the -1562 C/T polymorphisms in the
MMP2, MMP3 and MMP9 genes, respectively, and the risk and survival of lung cancer.
Methods: The case-control study includes 879 lung cancer patients and 803 controls from a Caucasian population
in Spain (CAPUA study). Genotypes were determined by PCR-RFLP. Odds ratios (OR) and 95% confidence intervals
(CI) were calculated using unconditional logistic regression. The Kaplan-Meier method, long-rank test and Cox’s
were used for the survival analysis.
Results: The MMP9 -1562 T/T genotype was associated with a statistically significant decreased risk of developing
lung cancer (OR = 0.23; 95% CI: 0.06-0.85), whereas no association was found for the MMP2 -735 C/T and MMP3
-1171 5A/6A polymorphisms. The MMP2 -735 T/T genotype was statistically significantly associated with a
decreased survival in non-small cell lung cancer (NSCLC) patients, identified as an independent prognosis factor of
survival (hazard ratio (HR) = 1.79; 95% CI: 1.00-3.20). In contrast, no association was found between the MMP3 -1171
5A/6A and the MMP9 -1562 C/T polymorphisms and survival.
Conclusions: These findings support the hypothesis that the MMP9 -1562 C/T polymorphism is associated with a
protective effect against the development of lung cancer and suggest that the MMP2 -735 C/T polymorphism
modify the length of survival in NSCLC patients.
Background
Lung cancer is one of the leading causes of death world-
wide. Approximately one million people, 850,000 men
and 330,000 women [1], die from lung cancer per year.
In Spain, lung cancer caused more than 20,000 deaths
in 2008; of these, 17,135 were men, and 3,035 were
women [2]. Despite some advances in the diagnosis and
treatment of lung cancer in the last several decades, the
prognosis of lung cancer remains poor. The 5-year over-
all survival rate of lung cancer is approximately 12% in
Spain and < 9% in developing countries [3]. The discov-
ery and application of specific prognostic biomarkers
could improve the survival rate of lung cancer [4].
Although some efforts have been made in this field
[5-9], stable biomarkers for both risk assessment and
clinical outcome predictors of lung cancer are still
scarce.
Matrix metalloproteinases (MMPs) are a family of
proteolytic enzymes that are capable of degrading var-
ious components of the extracellular matrix. They are
involved in all stages of cancer progression, not only in
the process of tumour invasion and metastasis, but also
in as proliferation, adhesion, migration, differentiation,
angiogenesis, senescence, autophagy, apoptosis and eva-
sion of the immune system [10]. The expression of
these MMPs by tumour cells may help increase the
invasive potential of tumour cells by allowing the remo-
delling of the extracellular matrix. In this sense, the
overexpression of MMP2, MMP9 and MMP3 has been
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detected in various types of human cancer, such oeso-
phageal cancer [11], gastric carcinoma [12], ovarian [13]
and lung cancer [14,15], and has been significantly asso-
ciated with tumour progression and decreased survival.
Studies based on the generation of loss-of-function ani-
mal models have provided definitive evidence of the
existence of MMPs with anti-tumour properties [16],
which supports the idea of an emerging and paradoxical
role of MMPs in tumour progression.
Functional polymorphisms in MMPs located in pro-
moter regions may influence the expression of the pro-
teins and thus contribute to individual differences in
cancer susceptibility and prognosis. To date, a large
number of studies have investigated the relationship
between genetic variants in the MMP2, 3 and 9 genes
and lung cancer risk [17,18]. However, only few studies
have explored the relationship between polymorphisms
in such genes and lung cancer survival, and these stu-
dies have displayed conflicting results [19-21]. Three
studies have been published that focus on non-small cell
lung cancer (NSCLC). Rollin et al. showed that patients
carrying the -735T allele in the MMP2 gene had a sig-
nificantly longer survival time compared with those car-
rying the -735C/C genotype, whereas the -1562C/T
polymorphism in the MMP9 gene was not associated
with survival time [19]. Heist et al. demonstrated that
the -735C/T and -1171 5A/6A polymorphisms in the
MMP2 and MMP3 genes, respectively, did not modify
the survival time in patients with stage I NSCLC [22].
Finally, Jin et al. showed that the -1562 C/T polymorph-
ism in the MMP9 gene is significantly associated with
survival [20]. Alternatively, there are no published stu-
dies that have analysed the association between poly-
morphisms in MMPs and survival time for small cell
lung cancers (SCLC).
The main aim of this study was to investigate the
relationship between 3 functional polymorphisms in
the regulatory regions of the human gelatinases MMP2
and MMP9 and the human stromelysin MMP3 and
lung cancer risk in the individuals from the CAPUA
study. The study also investigated whether polymorph-
isms in the MMP2, MMP3 and MMP9 genes may
modify the survival time among NSCLC and SCLC
patients.
Methods
Study subjects
The detailed methods of recruiting participants for this
hospital-based case-control study have been described
elsewhere [8,9,23]. Briefly, case incidences of histologi-
cally confirmed lung cancer were recruited in two main
hospitals of Asturias in Northern Spain [Cabueñes Hos-
pital in Gijón and San Agustin Hospital in Avilés],
which followed an identical protocol from October 2000
to June 2010 (CAPUA study). The controls were
selected from patients admitted to participating hospi-
tals for a list of diagnoses believed to be unrelated to
the exposures of interest (See additional file 1: List of
pathologies accepted for controls). The controls were
individually matched to the cases on the basis of ethni-
city, gender, and age (± 5 years). The main specific
pathologies of the final controls selected were as follows:
41.1% inguinal and abdominal hernias (ICD-9: 550-553),
32.5% injuries (ICD-9: 800-848, 860-869, 880-897), 8.8%
appendicitis (ICD-9: 540), and 13.3% intestinal obstruc-
tions (ICD-9: 560, 569, 574). The study was approved by
the ethical committee of the hospitals, and written con-
sent was obtained from each participant. A total of 879
cases and 803 controls agreed to participate in the study
and were interviewed. Of these, 841 cases (95.7%) and
742 controls (92.4%) provided a blood or buccal cell
sample. Until February 2010, when the DNA extraction
and genotyping was completed, we had samples from a
total of 841 cases and 657 controls. Sixteen individuals
(13 cases and 3 controls) were excluded because of pro-
blems in the DNA extraction. The following individuals
were excluded because of difficulties in genotyping,
mainly because of poor quality DNA: 56 individuals (12
cases and 44 controls) were excluded for MMP2, 232
individuals (112 cases/120 controls) were excluded for
MMP3, and 71 individuals (66 cases/5 controls) were
excluded for MMP9. Thus, the final study population
available for the analyses was 816 s/610 controls for
MMP2, 716 cases/534 controls for MMP3, and 762
cases/649 controls for MMP9.
Data collection
Information on known or potential risk factors for lung
cancer was collected personally through computer-
assisted questionnaires by trained interviewers during
the first hospital admission for diagnosis. Structured
questionnaires collected from each participant informa-
tion on age, gender, sociodemographic characteristics,
diet (including alcohol consumption), recent and prior
tobacco use, and personal and family history of cancer
(first-degree relatives). All eligible cases and controls
included in our analysis were Caucasian.
Participants were categorised by tobacco consumption
into three groups: those who have never been smokers,
defined as subjects who had not smoked at least one
cigarette per day regularly for six months or longer in
their lifetimes; former smokers, defined as regular smo-
kers who had stopped smoking at least one year before
the interview; and current smokers defined as subjects
who met none of the previous criteria. Smoking inten-
sity (pack-years (PY)) was defined as the number of
packs of cigarettes smoked per day multiplied by the
number of years of smoking.
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The dietary section of the questionnaire ascertained
the frequency of consumption and usual portion size of
117 food items (including alcoholic beverages) and was
used to estimate daily intake of alcohol and calories.
For each job held for a minimum of 6 months or
longer, we obtained information on the industry name,
production type, job title, and the year in which the job
began and ended. Occupations and industries were
coded using the 1977 Standard Occupational Classifica-
tion (Office of Federal Statistical Policy and Standards,
1977) and 1972 Standard Industrial Classification
schemes (Office of Federal Statistical Policy and Stan-
dards, 1972). Lastly, each coded occupation was cate-
gorised regarding whether it is included in list A.
Genotype determination
The polymorphisms in the promoters of the MMP genes
analysed in this study are shown in Table 1. The poly-
merase chain reaction (PCR) combined with the restric-
tion fragment length polymorphism (RFLP) was used to
determine the MMPs genotypes. Genomic DNA used
for the assay was extracted from peripheral blood sam-
ples (96.5% of total samples) or exfoliated buccal cells
(3.5% of total samples) as previously described [24]. For
quality control, genotyping was repeated randomly in at
least 5% of the samples, and two of the authors indepen-
dently reviewed all results. Another quality control
method was to take 50 blood and mouthwash samples
from the same participants to ensure the reliability of
the genotyping results of the mouthwash samples. In
both quality controls, no differences were found. PCR
reactions were carried out in a total volume 10 μl con-
taining 20 ng of genomic DNA, 0.25 mM of each dNTP
(Ecogen, Biologia Molecular S.L.), 0.2 units of Taq poly-
merase (Biotools, Inc.) and 2.5 pmol of each primer in a
1×PCR buffer (Sigma-Aldrich Co.). The details of the
primers and PCR conditions used for the amplification
of MMPs are shown in Table 1. A 5 μl aliquot of PCR
product was digested overnight at 37°C with 0.4 units of
the indicated restriction enzyme. After overnight diges-
tion, the products were separated on agarose gels and
stained with ethidium bromide (restriction enzymes are
shown in Table 1). To verify that the data obtained by
RFLP coincided with the allele sequence, representative
fragments were sequenced (data not shown).
Survival analysis
Survival questionnaires were collected by a pneumologist
trained to treat lung cancer patients who had been diag-
nosed at least 24 months earlier. Thus, a total of 879 eli-
gible cases were selected up until June of 2010. We
evaluated the overall survival sub-divided by NSCLC
(Non-Small Cell Lung Cancer) and SCLC (Small Cell
Lung Cancer) and on the basis of their different histo-
pathological presentation and clinical stages (NSCLC: I,
II, III, IV; SCLC: extended (ES) or limited (LS)).
Statistical analysis
Tests for the Hardy-Weinberg equilibrium among the
controls were conducted using observed genotype fre-
quencies and a c2 test with one degree of freedom. A
univariate analysis was first performed to compare the
distribution of age and gender and the frequencies of
alleles and genotypes. The differences in the distribution
between the cases and the controls were tested using
the c2, Fisher exact and the Mann-Whitney U-test,
where appropriate. The crude odd ratios (ORs) were cal-
culated by Wolf’s method [25]. A multivariate uncondi-
tional logistic regression analysis was performed to
calculate adjusted ORs and 95% confidence intervals
(CIs), adjusting for age, gender, family history of cancer
(first-degree relatives), tobacco consumption in pack-
years, alcohol consumption, calories, and occupation.
Survival time was calculated from the dates of lung can-
cer diagnosis to the date of death, which was collected
from the databases of the National Death Index of Min-
istry for Health and Social Policy. The survival curves
were constructed using the Kaplan-Meier method, and
the differences between the groups were tested by the
log-rank method. The multivariate analysis of the prob-
able prognostic factors for survival was performed using
Cox’s proportional hazard regression analysis. The rela-
tive risk with 95% confidence intervals was assessed,
adjusting for variables that were statistically significant
in univariate analysis. All statistical analyses were per-
formed with STATA version 8 software.
Table 1 Details of PCR and RFLPs conditions for polymorphisms studied
Gene Polymorphism Primer sequence PCR Conditions Enzyme
MMP9 -1562C/T (F) GCCCGCTCTGGATTATACG
(R) CTATCATCTCCTGGCCCCC
28 cycles: 94°C 30s, 65°C 30s, 72°C 30s SphI
MMP2 -735C/T (F) ATAGGGTAAACCTCCCCACATT
(R) GGTAAAATGAGGCTGAGACCTG
30 cycles: 94°C 30s, 62°C 30s, 72°C 30s HinfI
MMP3 -1171 5A/6A (F) TTTCAATCAGGACAAGACgaaGTTT*
(R) GATTACAGACATGGGTCACA
30 cycles: 94°C 300s, 53°C 30s, 72°C 30s XmnI
* modifíed bases
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Results
Population characteristics
The study population consisted of 879 lung cancer cases
and 803 controls drawn from the Caucasian population
of Asturias, Northern Spain. The distribution of demo-
graphic characteristics and clinical data is summarised
in Table 2. There were more current smokers (51.5% vs.
27.5%) and more heavy smokers (62.2 vs. 36.3 PY)
among the cases than among the controls (P < 0.001).
Histologically, NSCLC and SCLC represented the 81.9%
and 17.1% of lung cancer cases, respectively. Regarding
the clinical stage, 66.0% of NSCLC patients were in
stage III-IV, and 34.0% were in stage I-II, whereas 47.7%
of SCLC patients presented extended stage. The control
population was consistent with the Hardy-Weinberg
Equilibrium (HWE) for the polymorphisms in MMP9
and MMP3, but not for the polymorphism in MMP2.
Given that the first standard source for deviation from
the HWE is a genotyping error, the results obtained for
this polymorphism must be interpreted with caution.
The characteristics and clinical data of NSCLC and
SCLC patients are shown in Table 3. To date, 666
NSCLC (92.4%) and 137 SCLC (91.3%) cases have died.
Regarding the NSCLC patients, the clinical stage and
surgery status were associated with survival time (long-
rank p < 0.000). Furthermore, the univariate Cox regres-
sion analysis showed that the risk of death for NSCLC
was significantly associated with all clinical stages, and
late diagnosis is the clinical characteristic most asso-
ciated to death (compared with stage I, adjusted HR =
1.45; 95% CI: 1.05-2.00 for stage II; adjusted HR = 2.26;
95% CI: 1.83-2.79, for stage III; and adjusted HR = 3.97;
95% CI: 3.19-4.94 for stage IV), whereas the surgical
operation decreased the risk of death (adjusted HR =
0.32; 95% CI: 0.27-0.39). Alternatively, when the SCLC
patients were analysed, we found a significant increased
risk of death between ever smoking (adjusted HR =
2.51; 95% CI: 1.09-5.75) and individuals with extended
stage (adjusted HR = 2.19; 95% CI: 1.54-3.11), whereas
patients who received chemotherapy and radiotherapy
showed a significant decreased risk of death (adjusted
HR = 0.41; 95% CI: 0.26-0.62 and HR = 0.46; 95% CI:
0.32-0.64, respectively).
Associations between the MMP genotypes and lung
cancer risk
We examined the association between polymorphisms in
the MMP2, 3 and 9 genes and lung cancer risk (Table
4). A total of 816 cases and 649 controls were genotyped
up until February 2010 (816 cases and 610 controls for
the polymorphism in the MMP2 gene, 716 cases and
534 controls for the polymorphism in the MMP3 gene,
and 762 cases and 649 controls for the polymorphism in
the MMP9 gene). The variant genotype -1562 T/T in
the MMP9 gene was associated with a decreased risk of
developing lung cancer (adjusted OR = 0.23; 95% CI:
0.06-0.85; P = 0.027). When we carried out the stratified
analysis by selected variables, an association was found
between the polymorphism in the MMP9 gene and the
lung cancer risk for age and smoking status (adjusted
OR = 0.07; 95% CI: 0.01-0.58; and adjusted OR = 0.28;
Table 2 Characteristics of lung cancer cases and controls
patients of CAPUA study
Variable Cases (n =
879)
n (%)
Controls (n =
803)
n (%)
Pa
Gender
Male 785 (89.3) 688 (85.7)
Female 94 (10.7) 115 (14.3) 0.024
Age (yrs), mean (SD) 66.1 (10.6) 64.4 (11.2) 0.002
Smoking Status
Never 53 (6.1) 231 (29.1)
Ever 821 (93.9) 563 (70.9) 0.000
Former 369 (42.3) 337 (43.0)
Current 449 (51.5) 215 (27.5) 0.000
Pack-yearsb, mean (SD) 62.2 (36.2) 36.3 (30.8) 0.000
Family history of cancer
No 486 (58.3) 473 (60.3)
Yes 347 (41.7) 311 (39.7) 0.416
Lung cancer 91 (10.9) 52 (6.6)
Other cancers 256 (30.7) 259 (33.0) 0.009
Histological types
Squamous cell carcinoma 358 (40.7)
Adenocarcinoma 264 (30.0)
Small cell carcinoma 150 (17.1)
Non-differentiated 54 (6.1)
Large cell carcinoma 24 (2.7)
Others 15 (1.7)
Clinical diagnosis 6 (0.7)
Missing 8 (0.9)
Clinical stages
NSCLC
I 186 (25.9)
II 58 (8.1)
III 245 (34.1)
IV 229 (31.9)
SCLC
LS (Limited stage) 78 (52.3)
ES (Extend stage) 71 (47.7)
Calories, mean (SD) 2405.6 (845.4) 2276.9 (700.4) 0.045
Alcohol consumption (gr),
mean (SD)
26.4 (39.7) 22.2 (35.5) 0.033
Occupation (list A)
No 703 (80.7) 677 (87.1)
Yes 168 (19.3) 100 (12.9) 0.000
a Two-sided c2 test and Mann-Whitney where appropriate
b Pack-years for ever smokers
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95% CI: 0.08-1.01, respectively) [Data not shown]. In
contrast, no association was found between the -735 C/
T and -1171 5A/6A polymorphisms in the MMP2 and
MMP3 promoter genes and lung cancer risk (adjusted
OR = 0.86; 95% CI: 0.35-2.13; P = 0.749 and adjusted
OR = 1.19; 95% CI: 0.84-1.67; P = 0.331, respectively).
Associations between the MMP genotypes and NSCLC
and SCLC survival
When the Kaplan-Meier survival curves and the Cox
regression analysis were used to assess the associations
between the MMPs polymorphisms and survival time,
NSCLC cases with the MMP2 -735 T/T genotype
showed a lower survival time than the individuals with
C/T or C/C genotypes (P = 0.035) (Figure 1). In addi-
tion, the multivariate analysis used to delineate signifi-
cant prognostic factors for survival, showed that the T/
T genotype in MMP2 was an independent prognostic
factor for overall survival after adjustment for age, gen-
der, pack-years, histological types, clinical stage, surgical
operation status and chemotherapy (adjusted HR = 1.79;
95% CI: 1.00-3.20) (Table 5). However, the patients with
SCLC and the -735 T/T genotype did not have statisti-
cally significant results (adjusted HR = 1.25; 95% CI:
Table 3 Characteristics and clinical data of 721 NSCLC and 150 SCLC patients of CAPUA study
Variables NSCLC SCLC
Patients Deaths MST
(months)
Log-rank HR 95% CI Patients Deaths MST
(months)
Log-rank HR 95% CI
n % n %
Gender 0.293 0.053
Male 643 89.2 598 9.3 1.00 134 89.3 123 8.3 1.00
Female 78 10.8 68 12.5 0.87 0.68-1.12 16 10.7 14 14.5 0.57 0.32-1.02
Age (years) 0.083 0.041
≤ 68 375 52.0 342 11.3 1.00 79 52.7 69 9.8 1.00
> 68 346 48.0 324 8.2 1.15 0.98-1.34 71 47.3 68 7.6 1.42 1.01-2.00
Smoking Status 0.585 0.025
Never 45 6.3 41 10.5 1.00 7 4.7 6 54.2 1.00
Ever 672 93.7 621 9.5 0.92 0.67-1.26 142 95.3 130 8.4 2.51 1.09-5.75
Former 307 45.8 284 9.4 0.809 0.90 0.65-1.25 59 41.8 54 7.5 0.022 2.88 1.29-6.43
Current 363 54.2 335 9.5 0.93 0.67-1.28 82 58.2 75 9.2 2.24 1.02-4.91
Histological Types 0.608
Squamous cell carcinoma 358 49.6 335 10.9 1.00
Adenocarcinoma 264 36.6 240 10.2 1.05 0.89-1.24
Others 99 13.7 91 7.8 1.12 0.89-1.43
Clinical stages 0.000
I 186 26.1 151 26.1 1.00 0.000
II 58 8.1 51 19.7 1.45 1.05-2.00
III 244 34.3 238 9.6 2.26 1.83-2.79
IV 224 31.5 220 5.2 3.97 3.19-4.94
Limited stage (LS) 78 52.3 69 12.2 1.00
Extend stage (ES) 71 47.7 67 5.8 2.19 1.54-3.11
Surgical Operation 0.000
None 523 72.5 509 7.2 1.00
Yes 198 27.5 157 30.9 0.32 0.27-0.39
Chemo or Radiotherapy 0.469
None 301 41.7 262 6.9 1.00
Yes 420 58.3 412 11.7 1.06 0.90-1.24
Chemotherapy 0.000
None 29 19.3 28 1.6 1.00
Yes 121 80.7 109 9.9 0.41 0.26-0.62
Radiotherapy 0.000
None 74 49.3 71 5.4 1.00
Yes 76 50.7 66 12.1 0.46 0.32-0.64
NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer; MST: median survival
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0.17-9.31) (Table 6). However, individuals with the
MMP3 -1171 5A/5A or the MMP9 -1562T/T genotypes
did not show a statistically significant association with
survival time either in NSCLC patients (adjusted HR =
0.92; 95% CI: 0.72-1.18 and adjusted HR = 0.85; 95% CI:
0.32-2.30, respectively) (Table 5) or in SCLC patients
(adjusted HR = 0.67; 95% CI: 0.35-1.27 and adjusted HR
= 0.97; 95% CI: 0.29-3.25, respectively) (Table 6).
Discussion
We evaluated the effect of three polymorphisms in the
promoter regions of two human gelatinases, MMP2 and
MMP9, and the human stromelysin MMP3 on the risk
and survival time of lung cancer.
In this study, the distribution of the MMP2 genotypes
in controls is not in the Hardy-Weinberg equilibrium as
reported in Caucasian [19] and Asian [26] populations.
Although the explanation is not known, the random
recruitment of the healthy individuals, the reproducible
genotyping method and the consistence with the Hardy-
Weinberg equilibrium in several other polymorphic loci
[8,9,23], suggests that the controls in the present study
may reasonable be used in case-control investigations.
Our results suggest that the studied polymorphism in
the promoter region of the MMP9 gene is associated
with the risk of the development of lung cancer. Thus,
individuals with the MMP9 -1562 T/T genotype have
shown a protective effect against the development of
lung cancer compared to the reference genotype (-1562
C/C). In relation to survival analysis, the MMP2 -735 T/
T genotype was significantly associated with an unfa-
vourable survival prognosis in patients with NSCLC.
The MMP family comprises 23 human enzymes that
traditionally have long been associated with cancer inva-
sion and metastasis because of their ability to degrade
the extracellular matrix. However, recent studies have
showed that the roles of MMPs in tumour development
and metastasis are much more complex than was origin-
ally envisioned. In vitro and animal studies have demon-
strate that MMPs are also the key mediators of growth
factor activation, bioavailability and receptor signalling,
cell adhesion and motility, apoptosis and survival
mechanisms, angiogenesis, and inflammatory responses
and immune surveillance [10]. In this sense, high levels
of MMP2, MMP3 and MMP9 proteins have been impli-
cated in several malignancies including oesophageal,
renal, head and neck, oral, colorectal, NSCLC, breast
carcinomas and melanomas [27-34]. However, recent
studies have shown that several members of this family,
including MMP9, which were originally recognised as
pro-tumourigenic proteases [35], provide a protective
effect in different stages of cancer progression [36,37].
These experimental analyses support the results
obtained in our study where individuals with the MMP9
-1562 T/T genotype showed a decreased risk of develop-
ing lung cancer. Only two studies have evaluated the
association between the MMP9 -1562 C/T polymorph-
ism and lung cancer risk, both finding a non-statistically
significant association [19,26]. Several hypotheses can
Table 4 Analysis of polymorphisms and lung cancer risk
in CAPUA study population
MMPs Genotype Cases
n (%)
Controls
n (%)
ORa [95%
CI]
P P
trend
MMP9 C/C 581
(76.2)
483
(74.4)
1.00
C/T 174
(22.8)
148
(22.8)
0.96 0.69-
1.35
0.830
T/T 7 (0.9) 18 (2.8) 0.23 0.06-
0.85
0.027 0.202
MMP2 C/C 596
(73.0)
465
(76.2)
1.00
C/T 206
(25.2)
125
(20.5)
1.18 0.83-
1.67
0.359
T/T 14 (1.7) 20 (3.3) 0.86 0.35-
2.13
0.749 0.601
MMP3 6A/6A 185
(25.8)
139
(26.0)
1.00
6A/5A 367
(51.3)
276
(51.7)
1.19 0.83-
1.72
0.339
5A/5A 164
(22.9)
119
(22.3)
1.17 0.76-
1.81
0.483 0.331
aAdjusted by age, gender, pack-years, family history of cancer, occupation (list
A), alcohol consumption (gr), and calories
Figure 1 Kaplan-Meier survival curves of patients with NSCLC
by MMP2 genotypes, CAPUA study population, 2001-2010. The
individuals with T/T genotype showed significantly lower survival
rates than the individuals with the C/C genotype.
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explain this apparent discrepancy. First, Zhou et al. car-
ried out their study among the Chinese population,
whereas all individuals included in our study were Cau-
casians. In this sense, numerous differences have already
been reported concerning genotype frequencies and can-
cer susceptibility between Asian and Caucasian popula-
tions. For example, a recent meta-analysis for the
MMP1 1 G/2 G polymorphism found a statistically sig-
nificant association with cancer risk in European popu-
lations, whereas no association was found in Asian
populations [18]. Second, Rollin et al. analysed the risk
in 90 cases and 90 controls, though this sample size was
too small to yield a real association [19].
With regard to the MMP3 -1171 5A/6A polymorph-
ism, two studies have investigated the association
between this polymorphism and lung cancer risk, show-
ing a non-statistically significant association [17,18].
Thus, our findings are consistent with previous studies.
Finally, two studies have evaluated the lung cancer
risk for individuals with the -735C/T polymorphism in
the MMP2 gene, showing an 1.6-fold increased risk
associated with the -735C/C genotype in Asian popula-
tions [26] and no significant association in Caucasian
populations [19], which is in line with our results
(although it should be noted that Rollin’s study includes
only 90 cases).
Alternatively, in this study, we investigated the effects
of these three polymorphisms on the survival time of
816 lung cancer cases, subdivided on the basis of their
different histopathological presentation and clinical
stages (NSCLC: I, II, III, IV and SCLC: extended or lim-
ited). To date, a large number of studies have investi-
gated the relationship between variants in the MMP2, 3
and 9 genes and cancer susceptibility or metastasis,
including lung cancer [26,38]. However, only three stu-
dies have explored the relationship between the
Table 5 Association between genotypes of MMP9, 2 and 3 and NSCLC patients’ survival of CAPUA study
Genotypes Patients Deaths MST
(months)
Crude HR 95% CI HRa 95% CI
MMP9 n = 625
C/C 477 447 10.1 1.00 1.00
C/T 144 131 9.3 0.91 0.74-1.10 1.03 0.84-1.26
T/T 4 4 12.8 1.17 0.44-3.13 0.85 0.32-2.30
MMP2 n = 668
C/C 481 446 10.0 1.00 1.00
C/T 174 164 9.4 1.10 0.92-1.32 1.12 0.93-1.35
T/T 13 12 10.6 1.37 0.77-2.44 1.79 1.00-3.20
MMP3 n = 593
6A/6A 148 137 14.1 1.00 1.00
6A/5A 300 282 9.1 1.16 0.95-1.43 0.95 0.77-1.18
5A/5A 145 135 9.3 1.09 0.86-1.39 0.92 0.72-1.18
aAdjusted by age, gender, pack-years, histological type, clinical stage, surgical operation and radio and chemotherapy
MST: median survival time
Table 6 Association between genotypes of MMP9, 2 and 3 and SCLC patients’ survival of CAPUA study
Genotypes Patients Deaths MST
(months)
Crude HR 95% CI HRa 95% CI
MMP9 n = 129
C/C 98 88 9.5 1.00 1.00
C/T 28 25 8.9 1.08 0.69-1.69 1.06 0.67-1.68
T/T 3 3 24.5 0.67 0.21-2.12 0.97 0.29-3.25
MMP2 n = 140
C/C 112 102 8.8 1.00 1.00
C/T 27 24 8.9 0.90 0.58-1.41 0.98 0.60-1.58
T/T 1 1 9.2 1.34 0.19-9.70 1.25 0.17-9.31
MMP3 n = 116
6A/6A 37 34 7.6 1.00 1.00
6A/5A 61 54 9.4 0.84 0.55-1.30 0.79 0.50-1.26
5A/5A 18 16 13.4 0.69 0.37-1.26 0.67 0.35-1.27
aAdjusted by age, gender, pack-years, histological type, clinical stage, surgical operation and radio and chemotherapy
MST: median survival time
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polymorphisms in these MMPs and survival rates among
patients with NSCLC [19,20,22]. Rollin et al. explored
the effect of the MMP9 -1562 C/T and the MMP2
-735C/T polymorphisms in NSCLC survival among
Caucasian patients and found that the MMP9 -1562 C/
T polymorphism did not present a significant increase
in survival rate, in accord with our results (although it
should be noted that Rollin’s study includes only 90
patients). However, the homozygous individuals for the
MMP2 -735C allele had a shorter survival time than
those carrying the T allele (P = 0.02), and Cox’s propor-
tional hazard regression analysis demonstrated that this
polymorphism was an independent risk factor for a
shortened survival time (P = 0.045) [19]. Similarly to the
risk analysis, one possible reason for this discrepancy is
the relatively small sample size (90 patients). In another
study, Heist et al. investigated the association of five
polymorphisms, including the MMP3 -1171 5A/6A poly-
morphism, in 382 patients with stage I lung cancer,
finding that individual carriers of a variant genotype did
not present a significant increasebetter in survival rate.
To verify these results in our study, we analysed the
effects of the MMP3 -1171 5A/6A polymorphism in the
group of patients with stage I NSCLC and obtained
similar results (adjusted HR = 1.20; 95% CI: 0.72-2.00)
[data not shown]. Finally, a recent study of 561 NSCLC
patients in a Chinese population analysed the effects of
14 SNPs in MMPs genes in the overall survival of
patients with NSCLC and found that the MMP2 -735
T/T and MMP3 -1171 5A/5A genotypes did not
decrease survival time. However, large sample size stu-
dies in Caucasian and Asian populations are needed to
corroborate and validate these findings.
Our study is the first to analyse the effects of three
polymorphisms in the MMPs genes on the survival time
in SCLC patients. Our results indicated that the MMP2
-735 T/T genotype did not show significant differences
in survival time in patients with SCLC, whereas it was
associated with a significant decrease in survival among
patients with NSCLC. Studied polymorphisms in the
MMP3 and MMP9 genes showed no effect on the survi-
val time in both NSCLC and SCLC. The discrepancy of
these findings may be explained by different expressions
of MMPs between SCLC and NSCLC tissues. Thus, one
study among 45 patients with SCLC, where expression
was evaluated by Immunohistochemistry (IHC) for sev-
eral MMPs, showed a wide expression for all MMPs,
except for MMP2, whose expression was not detected
[39]. However, a recent meta-analysis showed that
MMP2 is highly expressed in NSCLC patients and that
decreased the survival time [40]. These results seem to
show that some MMPs may be more specific to NSCLC
tissues than to SCLC tissues.
Our study has several strengths, including high partici-
pation of eligible cases (rate of 91.4%) and quite a large
sample size from a homogeneous population of similar
ancestry (879 cases and 803 controls). Furthermore, all
of our cases were pathologically confirmed, and we
finally applied a strong quality control for genotyping.
Inevitably, the use of hospital-based controls is a poten-
tial limitation. Although there is always a chance of
recall bias because information on confounding variables
was obtained retrospectively, the estimations obtained
for the most important confounding variable (tobacco)
was nevertheless in line with the literature. Even though
our sample size is quite large because of the low allelic
frequency in the studied polymorphisms, our patient
and control groups with variant genotypes were prob-
ably not large enough to study the impact of these gene
polymorphisms on lung cancer risk. Therefore, further
studies with larger populations are necessary to reach
conclusions. Along the same line, the approach taken in
this manuscript (over-simplified with only 1 genetic var-
iant in each MMP gene) is a limitation. To properly
assess the association between the MMP genes and lung
cancer risk and survival, it would be preferable to take a
tagging variant approach.
Conclusions
In conclusion, our findings show a relationship between
the MMP9 variant genotype and protection against the
development of lung cancer and that the MMP2 variant
genotype modifies the survival time in NSCLC patients.
However, it is important to consider that MMPs poly-
morphisms may not occur as independent events and
could be associated with other polymorphisms in the
genome. Thus, there is still an important role for these
studies in candidate genes even in the current GWAS
era.
Additional material
Additional file 1: List of pathologies accepted for controls.
Acknowledgements
We are in debt to the patients who participated in the study. We would like
to thank Jesús Vioque and Eva Mª Navarrete-Muñoz (CIBER de Epidemiología
y Salud Pública (CIBERESP) and Universidad Miguel Hernández, Alicante) for
the diet analysis. We are also grateful to the study monitors from the
Unidad de Epidemiología Molecular - IUOPA. Finally, this work was partially
financed by FIS/Spain grant numbers FIS 03/0365 and FIS 06/0604 and the
University Institute of Oncology, supported by Obra Social Cajastur-Asturias,
Spain.
Author details
1Departamento de Medicina, Unidad de Epidemiología Molecular del Cáncer
del Instituto Universitario de Oncología del Principado de Asturias,
Universidad de Oviedo, 33006 Oviedo, Spain. 2Servicio de Neumología,
González-Arriaga et al. BMC Cancer 2012, 12:121
http://www.biomedcentral.com/1471-2407/12/121
Page 8 of 10
Hospital de Cabueñes, Gijón, Spain. 3CIBER Epidemiología y Salud Pública
(CIBERESP), Spain.
Authors’ contributions
PGA carried out molecular genetic studies and drafted the manuscript. TP
participated in the patient enrolment. AGA and AFS performed the statistical
analysis. MFLC participated in the molecular genetic studies and revised the
manuscript. AT conceived the study, participated in its design and
coordination, and revised the manuscript. All authors read and approved the
final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 29 November 2011 Accepted: 28 March 2012
Published: 28 March 2012
References
1. IARC: IARC International Agency for Research on Cancer. Cancer Mondial
2008 [http://www.iarc.fr,2008.].
2. INE: INE Instituto Nacional de Estadística. Deaths according to Cause of
Death 2008 [http://www.ine.es.2008].
3. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA
Cancer J Clin 2005, 55(2):74-108.
4. Ludwig JA, Weinstein JN: Biomarkers in cancer staging, prognosis and
treatment selection. Nat Rev Cancer 2005, 5(11):845-856.
5. Sweeney C, Nazar-Stewart V, Stapleton PL, Eaton DL, Vaughan TL:
Glutathione S-transferase M1, T1, and P1 polymorphisms and survival
among lung cancer patients. Cancer Epidemiol Biomarkers Prev 2003,
12(6):527-533.
6. Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC, Lynch TJ,
Neuberg DS, Christiani DC: XPD and XRCC1 genetic polymorphisms are
prognostic factors in advanced non-small-cell lung cancer patients
treated with platinum chemotherapy. J Clin Oncol 2004, 22(13):2594-2601.
7. Wu X, Zhao H, Amos CI, Shete S, Makan N, Hong WK, Kadlubar FF,
Spitz MR: p53 Genotypes and Haplotypes Associated With Lung
Cancer Susceptibility and Ethnicity. J Natl Cancer Inst 2002,
94(9):681-690.
8. Fernandez-Rubio A, Lopez-Cima MF, Gonzalez-Arriaga P, Garcia-Castro L,
Pascual T, Marron MG, Tardon A: The TP53 Arg72Pro polymorphism and
lung cancer risk in a population of Northern Spain. Lung Cancer 2008,
61(3):309-316.
9. Lopez-Cima MF, Gonzalez-Arriaga P, Garcia-Castro L, Pascual T, Marron MG,
Puente XS, Tardon A: Polymorphisms in XPC, XPD, XRCC1, and XRCC3
DNA repair genes and lung cancer risk in a population of northern
Spain. BMC Cancer 2007, 7:162.
10. Deryugina EI, Quigley JP: Matrix metalloproteinases and tumor
metastasis. Cancer Metastasis Rev 2006, 25(1):9-34.
11. Herszenyi L, Hritz I, Pregun I, Sipos F, Juhasz M, Molnar B, Tulassay Z:
Alterations of glutathione S-transferase and matrix metalloproteinase-9
expressions are early events in esophageal carcinogenesis. World J
Gastroenterol 2007, 13(5):676-682.
12. Sun WH, Sun YL, Fang RN, Shao Y, Xu HC, Xue QP, Ding GX, Cheng YL:
Expression of cyclooxygenase-2 and matrix metalloproteinase-9 in
gastric carcinoma and its correlation with angiogenesis. Jpn J Clin Oncol
2005, 35(12):707-713.
13. Schmalfeldt B, Prechtel D, Harting K, Spathe K, Rutke S, Konik E, Fridman R,
Berger U, Schmitt M, Kuhn W, et al: Increased expression of matrix
metalloproteinases (MMP)-2, MMP-9, and the urokinase-type
plasminogen activator is associated with progression from benign to
advanced ovarian cancer. Clin Cancer Res 2001, 7(8):2396-2404.
14. Bodey B, Bodey B Jr, Groger AM, Siegel SE, Kaiser HE: Invasion and
metastasis: the expression and significance of matrix metalloproteinases
in carcinomas of the lung. In Vivo 2001, 15(2):175-180.
15. Guo CB, Wang S, Deng C, Zhang DL, Wang FL, Jin XQ: Relationship
between matrix metalloproteinase 2 and lung cancer progression. Mol
Diagn Ther 2007, 11(3):183-192.
16. Overall CM, Kleifeld O: Validating matrix metalloproteinases as drug
targets and anti-targets for cancer therapy. Nat Rev Cancer 2006,
6(3):227-239.
17. McColgan P, Sharma P: Polymorphisms of matrix metalloproteinases 1, 2,
3 and 9 and susceptibility to lung, breast and colorectal cancer in over
30,000 subjects. Int J Cancer 2009, 125(6):1473-1478.
18. Peng B, Cao L, Wang W, Xian L, Jiang D, Zhao J, Zhang Z, Wang X, Yu L:
Polymorphisms in the promoter regions of matrix metalloproteinases 1
and 3 and cancer risk: a meta-analysis of 50 case-control studies.
Mutagenesis 2010, 25(1):41-48.
19. Rollin J, Regina S, Vourc’h P, Iochmann S, Blechet C, Reverdiau P, Gruel Y:
Influence of MMP-2 and MMP-9 promoter polymorphisms on gene
expression and clinical outcome of non-small cell lung cancer. Lung
Cancer 2007, 56(2):273-280.
20. Jin G, Miao R, Hu Z, Xu L, Huang X, Chen Y, Tian T, Wei Q, Boffetta P,
Shen H: Putative functional polymorphisms of MMP9 predict survival of
NSCLC in a Chinese population. Int J Cancer 2009, 124(9):2172-2178.
21. Bradbury PA, Zhai R, Hopkins J, Kulke MH, Heist RS, Singh S, Zhou W, Ma C,
Xu W, Asomaning K, et al: Matrix metalloproteinase 1, 3 and 12
polymorphisms and esophageal adenocarcinoma risk and prognosis.
Carcinogenesis 2009, 30(5):793-798.
22. Heist RS, Marshall AL, Liu G, Zhou W, Su L, Neuberg D, Lynch TJ, Wain J,
Christiani DC: Matrix metalloproteinase polymorphisms and survival in
stage I non-small cell lung cancer. Clin Cancer Res 2006, 12(18):5448-5453.
23. Marin MS, Lopez-Cima MF, Garcia-Castro L, Pascual T, Marron MG, Tardon A:
Poly (AT) polymorphism in intron 11 of the XPC DNA repair gene
enhances the risk of lung cancer. Cancer Epidemiol Biomarkers Prev 2004,
13(11 Pt 1):1788-1793.
24. Miller DP, Anderson RE, de Pablo JJ: Stabilization of lactate
dehydrogenase following freeze thawing and vacuum-drying in the
presence of trehalose and borate. Pharm Res 1998, 15(8):1215-1221.
25. Wolf FM: Meta-analysis: quantitative methods for research synthesis Beverly
Hills: Sage Publications; 1986.
26. Zhou Y, Yu C, Miao X, Wang Y, Tan W, Sun T, Zhang X, Xiong P, Lin D:
Functional haplotypes in the promoter of matrix metalloproteinase-2
and lung cancer susceptibility. Carcinogenesis 2005, 26(6):1117-1121.
27. Ohashi K, Nemoto T, Nakamura K, Nemori R: Increased expression of
matrix metalloproteinase 7 and 9 and membrane type 1-matrix
metalloproteinase in esophageal squamous cell carcinomas. Cancer 2000,
88(10):2201-2209.
28. Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N, Ross JS:
Increased expression of matrix metalloproteinases 2 and 9 and tissue
inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic
variables in renal cell carcinoma. Clin Cancer Res 2001, 7(10):3113-3119.
29. Franchi A, Santucci M, Masini E, Sardi I, Paglierani M, Gallo O: Expression of
matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix
metalloproteinase 9 in carcinoma of the head and neck. Cancer 2002,
95(9):1902-1910.
30. Tsai CH, Hsieh YS, Yang SF, Chou MY, Chang YC: Matrix metalloproteinase
2 and matrix metalloproteinase 9 expression in human oral squamous
cell carcinoma and the effect of protein kinase C inhibitors: preliminary
observations. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003,
95(6):710-716.
31. Kim TD, Song KS, Li G, Choi H, Park HD, Lim K, Hwang BD, Yoon WH:
Activity and expression of urokinase-type plasminogen activator and
matrix metalloproteinases in human colorectal cancer. BMC Cancer 2006,
6:211.
32. Lin TS, Chiou SH, Wang LS, Huang HH, Chiang SF, Shih AY, Chen YL,
Chen CY, Hsu CP, Hsu NY, et al: Expression spectra of matrix
metalloproteinases in metastatic non-small cell lung cancer. Oncol Rep
2004, 12(4):717-723.
33. Duffy MJ, Maguire TM, Hill A, McDermott E, O’Higgins N:
Metalloproteinases: role in breast carcinogenesis, invasion and
metastasis. Breast Cancer Res 2000, 2(4):252-257.
34. Shellman YG, Makela M, Norris DA: Induction of secreted matrix
metalloproteinase-9 activity in human melanoma cells by extracellular
matrix proteins and cytokines. Melanoma Res 2006, 16(3):207-211.
35. Egeblad M, Werb Z: New functions for the matrix metalloproteinases in
cancer progression. Nat Rev Cancer 2002, 2(3):161-174.
36. Scorilas A, Karameris A, Arnogiannaki N, Ardavanis A, Bassilopoulos P,
Trangas T, Talieri M: Overexpression of matrix-metalloproteinase-9 in
human breast cancer: a potential favourable indicator in node-negative
patients. Br J Cancer 2001, 84(11):1488-1496.
González-Arriaga et al. BMC Cancer 2012, 12:121
http://www.biomedcentral.com/1471-2407/12/121
Page 9 of 10
37. Takeha S, Fujiyama Y, Bamba T, Sorsa T, Nagura H, Ohtani H: Stromal
expression of MMP-9 and urokinase receptor is inversely associated with
liver metastasis and with infiltrating growth in human colorectal cancer:
a novel approach from immune/inflammatory aspect. Jpn J Cancer Res
1997, 88(1):72-81.
38. Fang S, Jin X, Wang R, Li Y, Guo W, Wang N, Wang Y, Wen D, Wei L,
Zhang J: Polymorphisms in the MMP1 and MMP3 promoter and non-
small cell lung carcinoma in North China. Carcinogenesis 2005,
26(2):481-486.
39. Michael M, Babic B, Khokha R, Tsao M, Ho J, Pintilie M, Leco K,
Chamberlain D, Shepherd FA: Expression and prognostic significance of
metalloproteinases and their tissue inhibitors in patients with small-cell
lung cancer. J Clin Oncol 1999, 17(6):1802-1808.
40. Qian Q, Wang Q, Zhan P, Peng L, Wei SZ, Shi Y, Song Y: The role of matrix
metalloproteinase 2 on the survival of patients with non-small cell lung
cancer: a systematic review with meta-analysis. Cancer Invest 2010,
28(6):661-669.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/12/121/prepub
doi:10.1186/1471-2407-12-121
Cite this article as: González-Arriaga et al.: Genetic polymorphisms in
MMP 2, 9 and 3 genes modify lung cancer risk and survival. BMC Cancer
2012 12:121.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
González-Arriaga et al. BMC Cancer 2012, 12:121
http://www.biomedcentral.com/1471-2407/12/121
Page 10 of 10
